TG Therapeutics, Inc.
TGTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001001316
In the last 90 days, TG Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 434 institutions reported holding it in 13F filings for Q2 2026, worth $6.10B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $9.75B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $274.8K in total
- 1
- 13F holdersQ2 2026, +71 vs. previous quarter
- 434
- 13F valueReported value at the end of Q2 2026
- $6.10B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $616.3M
- +87.3% year over year
- Net income, FY2025
- $447.2M
- +1,812.4% year over year
- Free cash flow, FY2025
- -$25.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $259.9M
- +60.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 28.8M
- Shares sold short
- Change
- −821.2K
- −2.8% vs. previous
- Days to cover
- 18.89
- At average daily volume
Superinvestors holding TGTX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding TGTX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by TG Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 (view filing)5:00 PM ET | Sep 10 | 4 days | Charney Laurence NDirector | SSale | −5.00K | $54.96 | −$274.8K | −2.9%168.6K after | |
| Nov 25, 2025 (view filing) | Nov 24 | 1 day | Echelard YannDirector | SSale | −5.00K | $32.57 | −$162.8K | −2.2%223.8K after | |
| Sep 12, 2025 (view filing) | Sep 11 | 1 day | Lonial SagarDirector | SSale | −20.9K | $32.24 | −$672.3K | −18.1%94.1K after | |
| Jun 16, 2025 (view filing) | Jun 13 | 3 days | Echelard YannDirector | SSale | −10.0K | $36.94 | −$369.4K | −4.2%228.8K after | |
| Jan 7, 2025 (view filing) | Jan 3-6 | 4 days | Power Sean ACFO | SSale | −21.4K | $29.46 | −$629.3K | −3.1%660.6K after | 2 lots |
| Nov 12, 2024 (view filing) | Nov 11 | 1 day | Lonial SagarDirector | SSale | −5.00K | $30.44 | −$152.2K | −4.8%100.2K after | |
| Nov 12, 2024 (view filing) | Nov 11 | 1 day | Charney Laurence NDirector | SSale | −25.0K | $30.20 | −$755.0K | −10.5%212.5K after | |
| Nov 7, 2024 (view filing) | Nov 5 | 2 days | Echelard YannDirector | SSale | −20.0K | $24.48 | −$489.6K | −8.2%224.1K after | |
| Jun 20, 2024 (view filing) | Jun 17-20 | 3 days | Lonial SagarDirector | SSale | −25.9K | $16.69 | −$432.9K | −19.8%105.2K after | 2 lots |
| Mar 15, 2024 (view filing) | Mar 13 | 2 days | Lonial SagarDirector | SSale | −5.00K | $15.94 | −$79.7K | −4.4%108.9K after |
Top 10 13F holders, Q2 2026
See all 434 holdersThe largest institutional positions in TG Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 22,050,045 | $1.21B | 0.02% | −202,885−0.9% | Reduced |
| Vanguard Portfolio Management LLC | 7,963,266 | $437.5M | 0.02% | −310,713−3.8% | Reduced |
| State Street Corp | 7,786,471 | $427.8M | 0.01% | −863,295−10.0% | Reduced |
| Vanguard Capital Management LLC | 6,149,403 | $337.8M | 0.01% | −453,855−6.9% | Reduced |
| Geode Capital Management, LLC | 3,642,216 | $200.1M | 0.01% | +142,300+4.1% | Added |
| D. E. Shaw & Co., Inc. | 3,400,808 | $186.8M | 0.12% | +2,810,761+476.4% | Added |
| Soleus Capital Management, L.P. | 2,927,895 | $160.9M | 5.54% | −1,101,424−27.3% | Reduced |
| Price T Rowe Associates Inc | 2,767,656 | $152.1M | 0.02% | +2,134,922+337.4% | Added |
| Clearbridge Investments, LLC | 2,650,192 | $145.6M | 0.12% | −560,738−17.5% | Reduced |
| Congress Asset Management Co | 2,600,123 | $142.9M | 0.88% | +432,042+19.9% | Added |
Holders of 5% or more of TGTX
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of TG Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 13.80%21.2M shares | +1.00 ppfrom 12.80% | Oct 7, 20243 filings | Oct 27, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.26%8.40M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
| State Street Corp | 13G | 5.10%8.10M shares | +0.40 ppfrom 4.70% | Feb 3, 20234 filings | Nov 10, 2025 | SEC |
Politician trades
All politician trades in TGTX1 member of Congress reported 1 trade in TG Therapeutics, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Nov 6, 2020 |  Chris Jacobs House · NY | Sell (partial) | $1K-$15K |
House · NY · Nov 6, 2020
Sell (partial)$1K-$15K